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Abstract
We have previously reported that FAM188B showed signiﬁcant differential exon usage in cancers (NCBI GEO
GSE30727), but the expression and function of FAM188B is not well characterized. In the present study, we explored
the functions of FAM188B by a knockdown strategy, using siRNAs speciﬁc for FAM188B in colon cancer cell lines.
FAM188B is a novel gene that encodes a protein that is evolutionarily conserved among mammals. Its mRNA has been
found to be highly expressed in most solid tumors, including colorectal cancer. FAM188B knockdown induced cell
growth inhibition due to an increase in apoptosis in colon cancer cell lines. Interestingly, siFAM188B treatment
induced the upregulation and activation of p53, and consequently increased p53-regulated pro-apoptotic proteins,
PUMA and BAX. Proteomic analysis of FAM188B immunocomplexes revealed p53 and USP7 as putative FAM188B-
interacting proteins. Deletion of the putative USP7-binding motif in FAM188B reduced complex formation of FAM188B
with USP7. It is noteworthy that FAM188B knockdown resulted in a decrease in overall ubiquitination in the p53
immunocomplexes, as well as p53 ubiquitination, because USP7 is involved in p53 deubiquitination. FAM188B
knockdown inhibited both colony formation and anchorage-independent growth in vitro. In addition, FAM188B
knockdown by siRNA reduced tumor growth in xenografted mice, with an increase in p53 proteins. Taken together,
our data suggest that FAM188B is a putative oncogene that functions via interaction with USP7. Therefore, control of
FAM188B could be a possible target to inhibit tumor growth.
Introduction
Colorectal cancer (CRC) is the third most prevalent
cancer worldwide and is a major contributor to cancer
mortality1. CRC is heterogeneous disease, biologically
classiﬁed into three major groups according to their
molecular characteristics. The ﬁrst is the chromosomal
instable group, which accumulates mutations in speciﬁc
oncogenes and tumor-suppressor genes. The second class
is the microsatellite instability group, which leads to
genetic hyper mutation, and the third is distinguished by
CpG island methylation2. In addition, large-scale genomic
studies have been conducted to advance our
understanding of CRC at a molecular level, including The
Cancer Genome Atlas analysis of 276 colon cancer
patients3. Many critical pathways contribute to the
development of CRC, including APC, WNT, RAS-MAPK,
PI3K, TGF-β, TP53, and DNA mismatch repair3. How-
ever, despite these efforts, there is still lack of detailed
characterization for low to intermediate frequency
mutations or novel candidates.
Programmed cell death inhibits the development of
cancer naturally through apoptosis of abnormal cells, but
cancer develops when this mechanism is disrupted4.
Typically, when chromosomal abnormality occurs, the
expression of tumor-suppressor P53 is increased, leading
to apoptosis of the cells5. Regulation of p53 is controlled
by various post-translational modiﬁcations. The
ubiquitin-proteasome system (UPS) is the main pathway
for controlling protein integrity, and is central to the
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regulation of many cellular functions, notably including
cell survival and death6,7. Ubiquitination is a remarkably
complex, speciﬁc, three-enzyme (E1-E2-E3) cascade that
utilizes 2 E1, 10 E2, and hundreds of E3 ubiquitin ligases8.
Deubiquitinases (DUB, ubiquitin isopeptidase) are UPS
components that catalyze removal of an ubiquitin moiety
from poly-ubiquitin chains6; the human genome encodes
98 DUB genes classiﬁed into six families9. Thus, the
dynamic and combinatorial interactions between
ubiquitination and deubiquitination set the threshold
for apoptotic signaling10. For example, the E3 ubiquitin
ligase MDM2 ubiquitinates the tumor-suppressor p53, and
DUBs, such as ubiquitin-speciﬁc proteases USP2a, USP7,
USP10, USP22, and USP42, are involved in regulating the
stability of p53 and MDM2 by removing ubiquitin moi-
eties6,11–13. However, what determines whether p53 or
MDM2 is the primary USP substrate is not known10,14.
A substantial proportion of genes (59%) in the human
genome are reported as “hypothetical” and are annotated as
being of “unknown function”15. Hypothetical proteins are
predicted from nucleic acid sequences and their existence
has not been experimentally proven. Another feature of the
hypothetical protein is that it has low identity compared to
known proteins16. However, despite their hypothetical sta-
tus, which can be an obstacle to investigations of their
expression patterns and potential functions in cellular
pathways, such genes are often expressed to varying degrees
in disease and are therefore biomedically relevant17. Thus,
excluding “unknown” or “hypothetical” genes from analyses
of candidate targets removes the opportunity to explore
unprecedented molecular mechanisms that may be involved
in clinically signiﬁcant pathological dysfunctions. Recently,
a hypothetical protein, FAM63A, was characterized as a
new DUB family member, and the analysis of evolutionarily
conservation among human genomes identiﬁed FAM63B as
a homolog, and listed FAM188A and FAM188B as evolu-
tionarily distant members18.
In our previous study, FAM188B showed signiﬁcant
differential exon usage in cancers (NCBI GEO
GSE30727)19, but the expression and function of
FAM188B had not yet been characterized. However,
public database search revealed FAM188B was differen-
tially expressed in many cancer types, and CRC showed
signiﬁcantly elevated expression in tumor. Here, we provide
the ﬁrst data that FAM188B is a genuine gene that over-
expressed in CRC. In addition, we show that it functions in
sustaining cell survival in vitro, and regulates growth
in vivo. Our analyses revealed FAM188B intervenes in
p53 stability control through interactions with USP7.
Results
Upregulation of FAM188B expression in colorectal cancers
Our previous study indicated that FAM188B has sig-
niﬁcant differential exon usage and differential expression
in gastric cancer tissues19. To explore whether FAM188B
expression is altered in other cancers, we ﬁrst searched
messenger RNA (mRNA) expression proﬁles of cancer
cell lines using the Cancer Cell Line Encyclopedia (CCLE)
database20. Most solid tumor cell lines, including CRC,
showed a higher mRNA expression level of FAM188B
than tumors from lymphoma, leukemia, and B-cell or
chondrosarcoma (Fig. 1a). To verify FAM188B mRNA
expression, we carried out quantitative real-time PCR
(qRT-PCR) using various cancer and non-cancerous cell
lines (Fig. 1b). FAM188B mRNA expression was detected
to different levels in all cell lines tested, including CRC
cell lines. To determine its endogenous protein expres-
sion, we generated a polyclonal antibody against
FAM188B. Western blot analysis revealed that FAM188B
protein was expressed in all cell lines (Fig. 1c). FAM188B
protein levels appeared to be relatively low in human
dermal ﬁbroblasts (HDFs), which was correlated with low
mRNA levels. As FAM188B expression at both mRNA
and protein level were substantial in the CRC cell lines
(HCT-116, SW620, and HT-29), we further explored
public datasets regarding FAM188B expression in CRC
patients. FAM188B mRNA expression was highly
increased in multiple CRC datasets (TCGA colorectal 2,
p= 2.48 × 10−16; GSE20916, p= 6.59 × 10−7; GSE20842,
p= 2.68 × 10−26) from Oncomine database21 (Fig. 1d).
FAM188B downregulation leads to cell death in vitro
To understand the function of FAM188B, we knocked
down FAM188B expression using FAM188B-speciﬁc
siRNA in the colon cancer cell lines HCT-116, HT-29,
and SW620. Transfection of cells with siFAM188B
decreased FAM188B mRNA expression from 24–96 h as
determined by qRT-PCR (Fig. 2a and Supplementary
Figures 3a and 4a), whereas negative control (NC) siRNA
had little effect on FAM188B expression. Correspond-
ingly, FAM188B mRNA levels decreased. FAM188B pro-
tein levels were also reduced by siFAM188B, as
determined by western blot (Fig. 2b, Supplementary Fig-
ures 3b and 4b). To test the effects of FAM188B knock-
down on cell growth, we employed two different
siFAM188B RNAs (siFAM188B and siFAM188B-2).
When FAM188B was knocked down by either
siFAM188B or siFAM188B-2, HCT-116 cell growth
decreased with time (Fig. 2c, Supplementary Figures 3c
and 4c). A microscopic analysis of DAPI-stained cells also
revealed that siFAM188B treatment increased brightly
ﬂuorescent and fragmented nuclei, which is indicative of
apoptosis (Fig. 2d). As cell growth inhibition could occur
either by cell-cycle arrest or cell death, we examined the
effect of FAM188B knockdown on cell cycle. Interestingly,
the sub-G0/G1 population increased in the siFAM188B-
treated cells, which corresponds to apoptotic cells
(Fig. 2e). In addition, FAM188B knockdown increased
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Fig. 1 FAM188B expression levels in public database and validation in cell lines. a FAM188B mRNA expression levels in CCLE database. Box-
and-whisker plots show the distribution of mRNA expression for each cancer type. Line in the box indicates median and dashed line indicates mean.
b FAM188B mRNA levels were measured in cancer cell lines (HCT-116, SW620, HT-29, AGS, SNU-638, A549, U87, JIMT1, MDA-MB-231, and HeLa) and
non-cancer cell lines (HEK-293 and HDF). Error bar indicates S.D. c Proteins (25 μg) from indicated cell lines were subjected to western blotting
analysis using anti-FAM188B antibody. GAPDH was used as a loading control. Similar results were observed in three independent experiments. d
FAM188B expression comparison between normal and tumor patient tissues using TCGA, GSE20916, and GSE20842 data set. Upper and lower dots
indicate the maximum and minimum values. The middle line in the box indicates median (***p < 0.001)
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the population of annexin V/PI-stained cells (Fig. 2f).
Apoptosis induced by siFAM188B was not limited to
HCT-116 cells because compared with NC siRNA-treated
cells, siFAM188B treatment also increased annexin
V/PI-positive cells in other colon cancer cell lines,
HT-29 and SW620 (Fig. 2f, Supplementary Figures 3d and
4d). All these data suggest that downregulation of
FAM188B expression in colon cancer cells leads to
apoptosis.
FAM188B silencing activates p53 and its downstream
pathway
To investigate the mechanism of FAM188B involve-
ment in cell death, we searched for potential cellular
FAM188B-binding partners by liquid chromatography/
mass spectrometry (LC/MS)-MS (Fig. 3a). Mass peaks
from MS searches against the database identiﬁed a total of
104 unique proteins bound to FAM188B. These proteins
were analyzed using the DAVID server22 and String-DB23
Fig. 2 Effects of FAM188B knockdown on cell death. a, b HCT-116 cells were transfected with either NC siRNA or siFAM188B for indicated times.
The mRNA levels and protein levels of FAM188B were measured by qRT-PCR (a) and western blotting (b), respectively. c–f HCT-116 cells were
transfected with either NC siRNA, siFAM188B, or siFAM188B-2 and images for cell growth (c) and nuclei fragmentation (d) were taken at the indicated
times. White arrow heads indicate nuclei fragmentation (scale bar= 20 μm) (d). Cells were also processed for cell-cycle analysis by ﬂow cytometry;
dead cell population: sub-G0/G1 is indicated in (%) (e). For apoptosis analysis, after 72 h of siRNA transfection cells were stained with annexin V/PI,
followed by ﬂow cytometry (f) (PI-stained cells apoptosis population: UR and UL)
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to cluster proteins according to their involvement in
intracellular biological processes and evidence-based
interacting groups, respectively. As expected, based on
results obtained by FAM188B downregulation, many
FAM188B-binding proteins were involved in cell-cycle
regulation and apoptosis (Supplementary table 2). Nota-
bly, clusters on the interaction map of FAM188B-binding
proteins revealed several clusters including the tumor-
suppressor proteins p53 as well as USP7 (Fig. 3b, arrows).
Interestingly, when we immunoprecipitated p53 proteins,
we could observe that FAM188B as well as USP7 were in
the p53 immunocomplexes (Fig. 3c), indicating that
FAM188B forms a complex with p53.
Because p53 is an important regulator for cell death
control, we further examined a possible association of p53
in the siFAM188B-induced apoptosis in more detail.
When cells were stained for p53, more p53 were localized
in the nucleus in the siFAM188-treated cells than in the
Fig. 3 Analysis of FAM188B-interacting proteins. a FLAG-tagged FAM188B was overexpressed in HEK-293 cells and immunoprecipitated
complexes of FLAG-tagged FAM188B were resolved on SDS-PAGE gels. Image of Coomassie-blue staining of the gel is shown. b The resolved
proteins in (a) were processed for LC/MS-MS analysis and searched against String-DB to see the interactions in “Evidence View.” Black arrow indicates
interacting protein separately conﬁrmed by immunoprecipitation. c Validation of FAM188B interaction to USP7 and p53 by immunoprecipitation of
HEK-293 cell lysate with p53 (DO-1) antibody and immunoblotted with indicated antibodies
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NC siRNA-treated cells (Fig. 4a). Consistent with these
immunocytochemistry data, more p53 protein was
detected in the nucleus fraction than in the cytosolic
fraction when FAM188B was knocked down (Fig. 4b).
Next, we tested whether p53 is activated in the FAM188B
knocked-down cells by immunoblotting using antibodies
that recognize Ser15-phosphorylated p53 (active form of
p53)24. FAM188B knockdown increased p53 as well as
Ser15-phosphorylated p53, and thus enhanced protein
levels of p53-regulated genes, including p21, PUMA, and
BAX, which are in the apoptosis pathway (Fig. 4c). To
further test p53 activation transcriptionally, we performed
promoter assay using p21 promoter-luciferase construct
because p21 is known to be a p53 target gene25.
siFAM188B treatment increased the transcriptional
activity of p53 toward its downstream target p21 by
approximately twofold (Fig. 4d). Moreover, chromatin
immunoprecipitation (ChIP) assays using p53 antibodies
showed increased binding of p53 to BAX (Fig. 4e) and
PUMA promoters (Fig. 4f) in the siFAM188B-treated
cells. These results suggest that FAM188B down-
regulation activates p53, and thus upregulates apoptosis-
related genes, including BAX, and PUMA, and leads to
cell death.
FAM188B regulates p53 stability via interaction with USP7
To determine how FAM188B knockdown enhances p53
protein levels, we identiﬁed FAM188B-interacting pro-
teins revealed by LC/MS-MS (Fig. 3b). As FAM188B
silencing affects p53 levels, we tested whether USP7, a
deubiquitinase, and p53-interacting proteins detected in
LC/MS-MS experiments, can be detected as a FAM188B-
binding protein. In accordance with this, the online pro-
tein domain prediction site, “Eukaryotic Linear Motif
resources”26, also predicted the presence of a USP7-
binding motifs in FAM188B (Fig. 5a and Supplementary
Figure 1a). USP7 protein was detected in FAM188B
immunoprecipitates in the cells with FAM188B
Fig. 4 Effects of FAM188B knockdown on p53 activation. a HCT-116 cells were transfected with either NC siRNA or siFAM188B for indicated
times. Cells were then stained using anti-p53 antibody and Hoechst33342 for nucleus followed by confocal microscopy analysis (scale bar= 20 μm).
b After treatment of cells as in (a), cells were fractionated and cytosol and nuclear fractions were subjected to western blotting using indicated
antibodies. PARP and α-tubulin were used as nuclear and cytoplasmic markers, respectively. c After treatment of cells as in (a), cellular proteins were
analyzed by western blotting using indicated antibodies. d Transcriptional activation of the p21 promoter, a target of p53, was measured using a dual
luciferase assay. ***p < 0.001. The p53-responsive element of BAX (e) and PUMA promoter regions (f) was measured by ChIP qRT-PCR assays. Three
independent ChIP qRT-PCR assays of BAX-p53RE levels and PUMA-p53RE were normalized to input control, respectively
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overexpression (Fig. 5b), indicating a complex formation
of FAM188B with USP7. To investigate which motif of
FAM188B is responsible for its complex formation with
USP7, either FLAG-tagged wild-type or mutant FAM188B
with deletion of USP7-binding motif-1 (ΔUSP7-1) or
USP7-binding motif-2 (ΔUSP7-2) were overexpressed in
HCT-116 cells, followed by immunoprecipitation of
exogenous FAM188B using anti-FLAG antibodies. USP7
was consistently found in the wild-type FAM188B
immunocomplexes but USP7 levels decreased in the
mutant FAM188B immunocomplexes (ΔUSP7-2), sug-
gesting that USP7-2 motifs of FAM188B are important for
its complex formation with USP7 (Fig. 5c). Next, to
examine whether USP7 interacts with p53, we performed
a co-IP assay after etoposide treatment to increase p53
expression. Etoposide treatment resulted in an increase in
p53 and a decrease in FAM188B. P53 was found in the
USP7 immunocomplexes and this complex formation
increased with etoposide treatment (Fig. 5d). Next, we
tested whether FAM188B levels affect complex formation
of USP7 and p53. A basal level of USP7 was detected in
the p53 immunocomplexes. However, interestingly, this
complex formation appeared increased in the
siFAM188B-treated cells after 24 h, and it became weaker
at 48 h although the endogenous USP7 protein expression
was not changed by FAM188B silencing (Fig. 5e).
To test whether FAM188B is involved in p53 deubi-
quitination, we examined the change in the level of ubi-
quitinated p53 after FAM188B knockdown in the cells
expressing HA-tagged ubiquitin. Compared with NC
siRNA-treated cells, less p53 was detected in the HA-
immunoprecipitated complexes from siFAM188B-treated
cells (Fig. 5f). In addition, the level of HA-tagged ubiquitin
decreased in the p53 immunocomplexes from
siFAM188B-treated cells compared with those of NC
siRNA-treated cells. A lower level of endogenous ubi-
quitinated p53 was also detected in the p53 immuno-
complexes from siFAM188B-treated cells than those of
NC siRNA-treated cells (Fig. 5g).
FAM188B knockdown inhibits tumor growth in vivo
To further investigate the effect of FAM188B down-
regulation on tumor growth, we established a
shFAM188B-inducibile HCT-116 stable cell line. Dox-
ycycline induced FAM188B short hairpin RNA (shRNA),
which led to FAM188B downregulation (Fig. 6a).
FAM188B shRNA expression reduced the number of
colonies (Fig. 6b). Next, we examined the effects of
FAM188B knockdown on anchorage-independent colony
formation by soft agar assay. When HCT-116 cells were
treated with siFAM188B, anchorage-independent colony
formation was signiﬁcantly decreased (Fig. 6c). These data
indicated that FAM188B might have an oncogenic func-
tion. To test the effect of FAM188B silencing on tumor
growth in vivo, HCT-116 cells were xenografted into
BALB/c nude mice, and FAM188B small interfering RNA
(siRNA) was delivered by electroporation. Tumor volume
was regularly measured after treatment with FAM188B
siRNA. The growth of siFAM188B-treated tumors was
signiﬁcantly reduced from the ﬁrst week compared to that
of NC siRNA-treated tumors (Fig. 6d). When the tumors
were removed from the killed mice, siFAM188B-treated
tumors were smaller than the NC siRNA-treated tumors
(Fig. 6d). To verify the FAM188B knockdown in the
xenografted tumors, tumor tissues were processed for
immunostaining using anti-FAM188B antibodies. Immu-
nohistochemistry analysis showed that FAM188B protein
levels reduced, while p53 protein levels increased, in the
siFAM188B-treated tumors (Fig. 6e). These data indicate
that FAM188B expression is important for tumor growth
in vitro and in vivo. Taken altogether, our data indicate
that FAM188B has a critical oncogenic effect, possibly via
enhancing p53 ubiquitination and thus p53 down-
regulation. Therefore, targeting FAM188B could be a
good strategy to control tumor growth.
Discussion
Cancer progression is the result of various biological
processes, and may also involve unexplored functions of
novel/hypothetical genes, and/or variants of known genes.
Despite the tremendous effort devoted to analyze avail-
able genomic information, as much as 59% of human
genes were annotated as “hypothetical” when the human
genome was ﬁrst reported15,27, and 24–31% of entrez/
ensemble database entries are currently annotated as
“uncharacterized”17. Our previous study, proﬁling exon
usage in gastric cancer, identiﬁed FAM188B as a gene that
was signiﬁcantly alternatively spliced between gastric
cancer and adjacent normal tissue. Until now, FAM188B
was annotated as a hypothetical gene for which the only
evidence for function was its transcript; no conﬁrmation
of its expression at the protein level had yet been
provided.
Before we characterized the function of FAM188B, we
ﬁrst analyzed the evolutionary conservation of the protein
sequences among species, because a biologically impor-
tant gene would be preserved in the genome, even if its
function is not known. We obtained 15 orthologous
protein sequences to FAM188B from bony ﬁsh to chim-
panzee from GenBank and aligned these sequences with
human FAM188B (Supplementary Figure 1a) and com-
pared the evolutionary distance among them (Supple-
mentary Figure 1b). All of the homologs showed high
similarity, and the sequence similarity of DUF4205
(domain of unknown function: IPR025257)28 among
mammalian FAM188B homologs was >76% (Supple-
mentary Figure 1a). According to the cladogram, human
FAM188B was closely related with the other orthologues
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Fig. 5 USP7 interacts with FAM188B and knockdown of FAM188B regulates p53 deubiquitination. a Predicted position of seven USP7-binding
motifs were indicated on FAM188B protein. ΔUSP7-1 and -2 are the positions of deletion mutants to analyze FAM188B-USP7 interaction. b Co-
immunoprecipitation of overexpressed FAM188B and USP7 in HCT-116 cell. c Veriﬁcation of the interaction between FAM188B and USP7 using
overexpression of wild-type and the predicted USP7-binding motif deleted FAM188B constructs. d Lysates from HCT-116 cells treated with or without
etoposide (5 μM) were immunoprecipitated and immunoblotted with antibodies shown in the ﬁgure. e FAM188B silencing increased the interaction
between USP7 and p53. Cell lysates from HCT-116 cells treated with NC siRNA or siFAM188B for 24 and 48 h were immunoprecipitated with anti-p53
antibody and immunoblotted with anti-USP7 antibody. f, g Knockdown of FAM188B reduces ubiquitinated p53. f HA-tagged ubiquitin (5 μg) was
transfected to HCT-116. Cell lysates from HCT-116 treated with NC siRNA or siFAM188B were immunoprecipitated by anti-HA antibody and
immunoblotted with indicated antibodies. g Cell lysates from HCT-116 co-transfected with HA-tagged ubiquitin and NC siRNA or siFAM188B were
immunoprecipitated by anti-p53 (DO-1) antibody and immunoblotted with indicated antibodies
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Fig. 6 (See legend on next page.)
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from primates such as Pan troglodytes (chimpanzee),
Pongo abelii (orangutan), but far from amphibian Xenopus
tropicalis (Supplementary Figure 1b). These results sug-
gest that FAM188B might be conserved through the
evolutionary lineage of the vertebrates for a biologically
indispensable function.
We ﬁrst determined whether this gene is a protein-coding
gene or a non-coding gene. The mature mRNA sequence of
FAM188B from the colon cancer cell line HCT-116 showed
a poly-A signal sequence in its 3′ UTR (data not shown),
suggesting that this gene could indeed encode a protein.
This evidence led us to generate a rabbit polyclonal anti-
body to detect the FAM188B protein. Using the results of
anti-FAM188B-speciﬁc antibody, we could detect endo-
genously or overexpressed FAM188B protein by immuno-
blotting and immunohistochemistry (Supplementary
Figure 2). Furthermore, as revealed by transcriptome pro-
ﬁles of the public databases including the CCLE, Oncomine,
and NCBI GEO29, the expression of FAM188B was sig-
niﬁcantly enhanced in tumors at the mRNA level. These
results suggest that FAM188B has important housekeeping
functions in maintaining cell viability.
Having obtained evidence of endogenous expression, we
explored the functional implications of elevated
FAM188B expression in tumors by suppressing transla-
tion of its mRNA using a siRNA approach. This loss-of-
function study showed that knockdown of FAM188B
resulted in a signiﬁcant increase in apoptotic cellular
phenotypes, including accumulation of a sub-G0/G1 cell-
cycle population, fragmented nuclei, and an increase in
the dead cell population. These phenotypic changes were
also observed in other cancer type cell (AGS, a gastric
cancer cell; Supplementary Figure 5), thus providing
strong evidence of the potential role of FAM188B as an
oncogene or regulator of oncogenic pathways. However,
identifying genuine interacting partners—a key to the
known world of biological pathways—is crucial to
understanding the working mechanisms of this unknown
protein. The catalog of FAM188B-interacting proteins
was deﬁned through immunoprecipitation of FAM188B
followed by LC/MS-MS analysis. A clustering of these
proteins according to their gene ontology (GO) biological
process showed that the major clusters were “protein
translation” and “cell death/apoptosis,” followed by
“chromatin regulation” and “RNA-binding proteins”
(Supplementary Table 2). Among these biological pro-
cesses, cell death and protein degradation categories were
of interest, because knockdown experiments suggested
that this protein might be involved in regulating cell
survival. Thus, we veriﬁed the FAM188B-interacting
proteins identiﬁed by mass spectrometry using co-
immunoprecipitation, and then proceeded to characterize
FAM188B functions related to cell death. Immunopreci-
pitation using an anti-p53 (DO-1) antibody conﬁrmed the
interaction of FAM188B with p53 (Fig. 3c). Intriguingly,
GO analyses categorized several proteins into an “ubi-
quitin-dependent protein” group; among them was USP7
(also known as HAUSP), which clustered with p53 as a
FAM188B-interacting protein (Fig. 3b). USP7 is known to
stabilize p53 by deubiquitinating it, as well as its inhibitor
MDM230,31. As such, USP7 has come to be considered a
therapeutic target in many cancers6,13. In breast cancer,
TSPYL5 was reported to reduce p53 levels through phy-
sical interactions with USP732. In addition to USP7,
USP2a and USP10 are also involved in regulating p53
ubiquitination in different contexts6; thus, evidence sup-
porting USP7 as the major p53 modulator is inconclusive.
In our study, however, the amount of FAM188B-bound
USP7 dramatically increased upon FAM188B over-
expression in HCT-116 cells. Conversely, FAM188B
downregulation increased unbound USP7 and this free
USP7 may decrease the level of ubiquitinated p53.
The fact that USP7 plays a pivotal role in deubiquitinating
both p53 and MDM2, as noted above, seemingly
undermines the interpretation that USP7 is a
p53 stabilizer. This may be the reason why the decrease of
ubiquitinated p53 in siFAM188B-treated cells was not
extreme (Fig. 5g). However, the shorter half-life of MDM2
compared to p53, as a result of MDM2 self-
ubiquitination14,33, may ultimately lead to cell death
through accumulated p53. If a mediator exists that could
be the answer to the questions “What determines
whether p53 or MDM2 is the primary USP7 substrate?”10
and “What determines how USP7 is regulated?”14,
FAM188B might be that mediator. In tumor cells, high
levels of FAM188B would be predicted to function by
(see ﬁgure on previous page)
Fig. 6 Oncogenicity of FAM188B conﬁrmed in vitro and in vivo. a mRNA expression in HCT-116 shRNA stable cell lines was measured by
quantitated real-time PCR. Doxycycline induces shRNA in HCT-116. Error bar indicates S.D. b shRNA stable HCT-116 cells were treated with
doxycycline to induce shRNA expression and incubated 7 days to form colonies and stained with crystal violet. The number of colonies of Dox (+) is
signiﬁcantly reduced compared to Dox (−). c HCT-116 cells (5.0 × 103) treated with NC siRNA or siFAM188B was cultured in soft agar for 18 days. The
colonies were stained with INT solution. All experiments were performed triplicate. d HCT-116 cells (2.0 × 106) were injected into the nude mice (n=
7) subcutaneously and tumor growth was monitored twice a week. When tumor size reached 30mm3, siRNAs were treated a week for 3 weeks. Black
arrow indicates the siRNA treatment. Tumor size was measured at indicated time points (representative images of tumors; NC siRNA (top lane) and
siFAM188B (bottom lane)). e Immunohistochemistry of FAM188B and p53 protein detected from tumor tissues from mice using control IgG, anti-
FAM188B, and anti-p53 (FL393) antibodies (scale bar= 100 μm)
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eliminating p53 and keeping it at a low level to allow
tumor cells to grow. Silencing of USP7 decreased the p53
level and increased ubiquitinated-p53. However, double
silencing of USP7 and FAM188B restored the p53 level
(Supplementary Figure 6a). Therefore, elevated expression
of FAM188B in tumor tissues suggests that FAM188B
would inhibit p53 activation and thereby provide toler-
ance against stressful conditions (Supplementary Fig-
ure 6b). On the other hand, many tumors have mutations
in or deletion of p53 gene, therefore, the effect of elevated
FAM188B may not be exclusive on the tumorigenesis in
such tumors.
The most intriguing result in this study was conﬁrming
the tumorigenicity of FAM188B. The colony forming
ability of FAM188B was signiﬁcantly abolished by silen-
cing its expression in vitro. Interestingly, in soft agar
colony formation assays, a golden standard to determine
cellular transformation and tumorigenicity34, FAM188B
silencing showed dramatic reduction of anchorage-
independent colony growth (Fig. 6b). Moreover, in vivo
tumor growth assays also revealed that FAM188B led to a
dramatic difference in tumor masses of xenografted HCT-
116 in BALB/c nude mice. Accordingly immunohisto-
chemical analyses revealed that FAM188B is a vital gene
for proliferation or survival. Although additional studies
with human tissue are also required to assess feasibility,
these results suggest that FAM188B overexpression could
be used as a predictive biomarker for cancer diagnosis,
and suggests that inhibiting FAM188B activity could be
utilized as the putative target of cancer progression.
Although further studies are required to reveal how
FAM188B expression is regulated, our ﬁndings clearly
support the conclusion that FAM188B is an important
regulator of p53 stability in growing cells.
In this study, the hypothetical protein FAM188B was
revealed to be a genuine protein whose expression is
signiﬁcantly elevated in colon cancer cell lines. On the
basis of FAM188B loss-of-function analyses, we suggest
that FAM188B functions to sustain cell viability by
decreasing p53 activation, through inhibition of the deu-
biquitinase USP7. This provides signiﬁcant insight into
the importance of FAM188B in sustaining cell survival, as
well its use as a potential target in cancer therapy. Further
research on the details of FAM188B regulatory mechan-
isms, as well conditions with p53 mutations, will increase
our understanding of FAM188B as a potential therapeutic
target.
Materials and methods
Datasets from the public databases
Datasets were obtained from Cancer Cell Line Ency-
clopedia (CCLE) database (https://portals.broadinstitute.
org/ccle)20 for cancer cell lines. Datasets of colorectal
adenocarcinoma with >2× of expression difference with p-
value <0.001 between normal and tumor tissues were
obtained from Oncomine (https://www.oncomine.org/)21.
Cell lines
The human cell lines used in these studies (HCT-116,
SW620, HT-29, AGS, SNU-638, A549, U87, JIMT1,
MDA-MB-231, HeLa, HEK293, and HDF) were obtained
from American Type Culture Collection (Manassas, VA,
USA) or Korean Cell Line Bank (Seoul, Korea). All the
cells were cultured with designated media (Corning,
Manassas, VA, USA) supplemented with 10% fetal bovine
serum (Corning) and 1× penicillin streptomycin (Invi-
trogen, Carlsbad, CA, USA) at 37 °C containing 5% CO2.
Reverse-transcription polymerase chain reaction and
quantitative RT-PCR
First-strand complementary DNA synthesis and qRT-
PCR were performed as our previous report using a
LC480 real-time PCR machine (Roche, Switzerland)35.
Primers spanning two consecutive exons (Supplementary
Table 1) were designed using Primer3 software (http://
frodo.wi.mit.edu/primer3/)36.
Antibodies for immunoblot and immunocytochemistry
For the detection of FAM188B, we generate polyclonal
antiserum using FAM188B protein C-terminus peptides
(722–738 a.a: TISEDTDNDLVPPLELC) as antigen
(AbFrontier, Seoul, Korea) (Supplementary Figure 2). The
afﬁnity-puriﬁed serum was applied to immunoblots at
1:1000 dilutions in 5% skim milk/1× Tris-buffered saline
(TBS). The following antibodies were used to detect other
proteins in this study: FLAG M2 and β-actin from Sigma-
Aldrich (St. Louis, MO, USA); PUMA, USP7, p21, BAX
and PARP from Cell Signaling Technologies (Danvers,
MA, USA), and p53 (DO-1), p53 (FL393), phospho-p53
(ser15), and α-tubulin from Santa Cruz Biotechnology
(Dallas, TX, USA), and GFP (JL-8) from Clontech
(Mountain view, CA, USA).
Analyses of FAM188B expression knockdown
FAM188B expression was silenced by transfecting with
FAM188B-speciﬁc siFAM188B (Qiagen, Germany) target-
ing the sequence 5′-CTGACCATTGACACCACCAA-3′,
Allstar NC siRNA (Qiagen) at 5 nM using Lipofectamine
RNAiMAX (Thermo Fisher Scientiﬁc, San Jose, CA, USA).
Cell cycle was analyzed by ﬂow cytometry by staining
with propidium iodide (Sigma-Aldrich). Nuclear frag-
mentation in siRNA-treated cells stained with
Hoechst33342 (Sigma-Aldrich) was observed by confocal
microscopy at ×400 magniﬁcation. Annexin V assays for
the detection of apoptotic populations was carried out
using a BD FITC annexin V apoptosis detection kit I (BD
Pharmingen, San Jose, CA, USA) according to the man-
ufacturer’s protocol.
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Colony forming assay and soft agar assay
Doxycycline inducible HCT-116 shRNA (shFAM
188B#1: CTTTGGAAATACGGCTAACAA, #2: CAGAT
ACTTTCTGGATCACTT) stable cell lines (2 × 103) seeded
in six-well plates and 1 μg/ml of doxycycline (Sigma-
Aldrich) was treated for 1 week. Colony formation was
analyzed by ﬁxing with 4% formaldehyde and staining
with crystal violet solution (Sigma-Aldrich).
Onto the base agar (0.8%) dispensed into the wells,
siRNA-treated HCT-116 cells were seeded with top agar
(0.3%). Cells were cultured for 3 weeks with medium
change every 4–5 days, and stained with INT solution.
Proteomic analysis and proﬁling of interacting partners
FAM188B-interacting proteins from HEK-293 cells
transfected with pFLAG-FAM188B plasmid were immu-
noprecipitated with anti-FLAG-M2 agarose afﬁnity gel
(Sigma-Aldrich). Analyses were performed using an LTQ
XL linear ion trap mass spectrometer (MS) system
(Thermo Fisher Scientiﬁc). All MS/MS samples were
analyzed using Proteome Discover software (version v.1.4;
Thermo Fisher Scientiﬁc), set up to search the Uniprot
database and IPI human database.
Dual luciferase assay
HCT-116 cells were transfected with NC siRNA or
siFAM188B with pGL2-p21-luc (Addgene, Cambridge,
MA, USA) and pGL4.70hRluc (Promega, Madison, WI,
USA) plasmids. After 24 and 48 h, cells were collected,
and dual luciferase assays were performed according to
the manufacturer’s protocol (Promega) and measured
using a Victor3 reader (Perkin Elmer).
Chromatin immunoprecipitation assay
Collected nuclei from ﬁxed cells (1 × PBS/1% for-
maldehyde) were sonicated for 7.5 min (0.5 min on, 1 min
off cycles) using a Bioruptor (Diagenode, Denville, NJ,
USA). Fragmented genomic DNA was immunoprecipi-
tated with anti-p53 antibody (DO-1), and puriﬁed by
phenol/chloroform/isoamyl alcohol extraction. Ampliﬁ-
cation of BAX and PUMA genes was carried out using
SYBR green master mix with p53-RE primers37 using
LC480 PCR machine (Roche).
p53 ubiquitination assay
HCT-116 cells were co-transfected with HA-Ubi plas-
mid and NC siRNA or siFAM188B. MG132 treated for 4 h
before collection. One milligram of cell lysates were
immunoprecipitated with anti-p53 (DO-1) antibody and
immunoblotted with anti-HA antibody and vice versa. For
the input control, 20 μg of lysates were loaded and
immunoblotted with p53 (DO-1), ubiquitin, HA, and
GAPDH antibodies.
In vivo analysis of FAM188B silencing
HCT-116 (2.0 × 106) cells were subcutaneously injected
in 6-week-old male BALB/c nude mice (CAnN.Cg-
Foxn1nu/CrljOri, Orient Bio, Korea). When the tumor
size reached 30mm3, Allstars NC siRNA or siFAM188B
were injected into tumor via electroporation using
NEPA21 Super Electroporator TypeII (Nepa Gene Co.,
Chiba, Japan) every 7 days for up to 3 weeks. Tumor
volume was calculated by the modiﬁed ellipsoidal formula
(length × width × width)/2. The experiment procedure
and protocol was approved by Institutional Animal Care
and Use Committee in National Cancer Center of Korea
(NCC-16-231).
Immunohistochemical staining
Formaldehyde-ﬁxed parafﬁn-embedded tissue section
was used for immunohistochemical staining performed
with Discovery XT (Ventana Medical Systems, Tucson,
AZ, USA) using anti-FAM188B antibody (Atlas Anti-
bodies AB, Stockholm, Sweden). Parallel sections incu-
bated with normal IgG antibody instead of primary
antibodies were used as NCs.
Statistical analysis
The statistical signiﬁcance of differences between
groups was determined using χ2-test and Student’s t-test.
p-values <0.05 were considered statistically signiﬁcant.
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